AstraZeneca’s cancer drug Iressa fails in trial

Share this article:
AstraZeneca (AZ) said Friday it would it would voluntarily cease promotion of its new lung cancer drug Iressa after clinical trial results showed it failed to significantly prolong the life of patients.
AZ said although trial data showed there was a statistically significant improvement in tumor shrinkage with Iressa patients that did not translate into a statistically significant survival benefit.
The company was consulting with regulatory authorities to determine the impact of the results.
The news about Iressa is the latest in a series of setbacks for U.K. drug maker. In October, the FDA indicated that AZ's drug Crestor was under review. And in September, AZ failed to gain regulatory approval for its blood thinning indication Exanta.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.